Aditxt and Ignite announce merger plans with strategic partner
Ignite will separate from Aditxt and is expected to become an independent public company called Ignite Proteomics.
Drug Development
MHRA to roll out new AI sandbox for medicines development
J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline
Pfizer’s Hympavzi secures FDA expanded indications for haemophilia
Sanofi and Owkin partner to develop next-generation biopharma AI agents
EC grants marketing authorisation for IntraBio’s Aqneursa
Pfizer signs licence agreement with Chai for AI drug discovery
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
